JPMorgan Chase & Co. cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,126,092 shares of the biopharmaceutical company's stock after selling 160,193 shares during the quarter. JPMorgan Chase & Co. owned approximately 4.82% of Intra-Cellular Therapies worth $428,131,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in ITCI. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC raised its holdings in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 240 shares during the period. Venturi Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB bought a new position in shares of Intra-Cellular Therapies in the third quarter worth $97,000. Finally, Quarry LP grew its position in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 1,300 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.
Intra-Cellular Therapies Price Performance
Shares of ITCI remained flat at $131.87 during mid-day trading on Thursday. The firm has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.98. The company has a 50-day moving average price of $129.43 and a 200-day moving average price of $100.82.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have issued reports on ITCI shares. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $106.23.
Read Our Latest Stock Analysis on ITCI
Intra-Cellular Therapies Profile
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Articles
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
